Wells Fargo Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.
Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.